EMA Application withdrawn: Belviq — Arena Pharmaceutical Enterprises Limited

View source ↗

Summary

The EMA withdrew the application for Belviq from Arena Pharmaceutical Enterprises Limited in the obesity/overweight therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Belviq (lorcaserin)

Snippet

Status: Application withdrawn. Therapeutic area: Obesity;Overweight. MAH: Arena Pharmaceutical Enterprises Limited. Decision date: 31/05/2013